Similarly, treatment with mAbs targeting podocalyxin [37], HER2 [38], glypican-1 [39], cell surface plectin 1 [40], galectin-9 [41], RON [42], BAG3 [43], CLDN18.2 [44], mesothelin [45], vimentin [46] and doublecortin-like kinase 1 [47] inhibited the growth of pancreatic tumours in xenograft models. The gene discussed is MSLN; the disease is pancreatic neoplasm.